Frontal Assessment Battery in Addiction: A Comparative Study

INTRODUCTION

Executive functions (EFs) encompass a critical set of higher-order cognitive processes fundamental to human behavior and adaptation. These intricate mental operations include working memory, which allows for the temporary holding and manipulation of information; reasoning, enabling logical thought and problem-solving; task flexibility, the ability to switch between different mental sets or demands; and the essential processes of planning and execution, which govern goal-directed actions. EFs are primarily orchestrated by the frontal lobes of the brain, making them indispensable for everyday activities ranging from simple decision-making to complex strategic planning. Dysfunction in these areas can profoundly impact an individual’s ability to regulate behavior, adapt to new situations, and achieve personal objectives.¹

Given the critical role of EFs, the development of reliable and efficient tools for their assessment is paramount in clinical and research settings. The Frontal Assessment Battery (FAB) was specifically designed as a concise and effective instrument for evaluating executive dysfunctions. It serves as a rapid and efficient bedside battery aimed at detecting frontal lobe dysfunction across a diverse range of patients. The FAB is structured into six distinct subtests, each meticulously crafted to assess a particular “executive” function believed to be subserved by the frontal cortex. The total score on the FAB ranges up to a maximum of 18, with higher scores indicating superior executive performance. Notably, a cutoff score of 12 on the FAB demonstrates a sensitivity of 77% and a specificity of 87% in distinguishing between frontal dysexecutive type dementias and Alzheimer’s dementia, highlighting its diagnostic utility.²

The utility of the FAB extends beyond differential dementia diagnoses. It has been extensively employed in the assessment of various patient populations, including those with Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, Huntington’s disease, and other neurological conditions. Furthermore, the FAB has proven sensitive in detecting frontal lobe damage in stroke patients, underscoring its broad applicability in neurological assessment. Importantly, the FAB has also found application in the realm of substance abuse, indicating its relevance to the study of addiction.^3–7

Substance use disorders (SUDs) are recognized as chronic, relapsing brain diseases characterized by compulsive drug seeking and use despite harmful consequences. A growing body of evidence suggests that SUDs are associated with significant impairments in executive functioning. These impairments can manifest as difficulties in impulse control, decision-making, problem-solving, and emotional regulation, all of which contribute to the perpetuation of addictive behaviors and hinder recovery efforts. While the link between SUDs and executive dysfunction is increasingly recognized, comparative data specifically examining the extent and nature of these deficits across different types of substance use (e.g., alcohol, cannabis, opioids) remains limited, particularly in routine clinical settings. This gap in comparative data poses challenges for targeted interventions and personalized treatment approaches. Therefore, this study aims to fill this knowledge gap by assessing and comparing executive functioning using the FAB among individuals with alcohol, cannabis, and opioid use disorders, alongside a control group from the general population, to provide valuable insights into the differential impact of various substances on frontal lobe integrity and executive capabilities.^8–10

MATERIAL AND METHODS

This was a cross-sectional study done over a period from March 2024 to September 2024 at the Psychiatry outpatient department (OPD) of a tertiary care hospital in India. After obtaining clearance from the institutional ethics committee, a total of 120 adult participants were selected for the study. Out of these 120 participants, 30 each were selected using simple random sampling from four groups: normal population, patients with alcohol use disorder, cannabis use disorder, and opioid use disorder. Individuals from the normal population group were selected from the non-medico hospital staff, and they did not have any history of psychiatric disorder or any other medical comorbidities. The rest of the three groups of SUD were selected from patients attending our OPD. These patients also had no concurrent or any previous history of psychiatric disorder except for the current diagnosis, were evaluated in their first visit to our OPD, and were not on any chronic medications. They also did not have any polysubstance use and were not in an intoxicated or withdrawal stage.

Participants in the substance use groups were consecutively screened during their first OPD visit and enrolled using a computer-generated random number list after meeting inclusion criteria. Controls were selected from non-medical hospital staff using the same randomization procedure to minimize selection bias.

The age group for all the participants was 18–50 years. Groups were approximately matched for age and years of education. These variables were compared across groups using one-way ANOVA to check for significant differences. After fulfillment of selection criteria, the participants were explained the nature of the study, and written consent was taken from them. Socio-demographic details were obtained using a pretested questionnaire. Then the FAB was given to all the participants, and results were analyzed.

Data were analyzed using SPSS (version 24). Between-group differences were examined using independent-samples t-tests (each substance group vs. control) and one-way ANOVA. For transparency, effect sizes (Cohen’s d) and 95% confidence intervals (CIs) were calculated for mean differences. A Bonferroni adjustment (p × 3) was applied for the three pairwise comparisons; the overall pattern of significance remained unchanged. Statistical significance was set at p < 0.05 (two-tailed).

RESULTS

The demographics and other population characteristics are shown in Table 1, whereas Figure 1 displays the mean FAB scores across the normal population and SUD groups.

Close

Figure 1:

Mean FAB scores across normal population and substance use disorder (SUD) groups. FAB: Frontal assessment battery.

Export to PPT

Table 2 shows a comparison of means of FAB scores between different SUD groups with the normal population group using an unpaired t-test, and the differences are statistically significant (p-value <0.05) for all the comparison groups. Also, a one-way ANOVA form comparison between all four groups shows that there is a statistically significant difference in FAB scores among all the groups (p-value 0.027).

Effect sizes ranged from moderate (alcohol, d = 0.57) to large (cannabis, d = 0.83; opioid, d = 0.72). After Bonferroni adjustment for multiple comparisons, group differences remained significant for cannabis and opioid users.

Table 3 shows the correlation between the duration of substance use and FAB scores in the three groups of SUD. There is a negative correlation between duration of substance use and FAB scores, and the correlation is statistically significant in cases of cannabis use disorder and opioid use disorders.

DISCUSSION

This study was conducted to assess and compare EFs among individuals with SUDs and the normal population, using the FAB. The results show that patients with alcohol, cannabis, and opioid use disorders performed significantly worse on the FAB compared to the control group. This supports the idea that chronic substance use can impair frontal lobe functions, which are essential for goal-directed behavior, judgment, planning, and flexibility.^1–3

The cannabis use disorder group had the lowest average FAB scores, and 10% of participants in this group scored below the cut-off score of 12. Interestingly, this group also showed a strong and statistically significant negative correlation between the duration of cannabis use and FAB scores. This finding suggests that longer use of cannabis may be associated with worsening executive functioning, possibly due to its long-term impact on prefrontal cortical areas responsible for abstraction, motor programming, and cognitive flexibility.^4,7 These findings are similar to those reported in earlier studies where cannabis-dependent individuals showed marked executive dysfunction.^5,6,8

Similarly, the opioid use disorder group also had significantly lower FAB scores than the normal group. A statistically significant negative correlation was found between the duration of opioid use and FAB scores. Chronic opioid use is known to affect frontal lobe activity, possibly through changes in the dopaminergic and glutamatergic systems. These alterations can interfere with inhibitory control and decision-making abilities.^9–12

Although the alcohol use disorder group also showed significantly lower FAB scores than the normal population, the correlation between duration of use and FAB scores did not reach statistical significance. This could be due to variability in drinking patterns, periods of abstinence, or individual differences in brain resilience.¹³ Nonetheless, studies have shown that long-term alcohol use can affect brain structures, particularly in the frontal and prefrontal areas, leading to difficulties in planning, problem-solving, and social behavior.^14,15

The overall difference in FAB scores among all four groups was statistically significant, as shown by one-way ANOVA. This highlights that the FAB can serve as a quick and useful screening tool in clinical practice to detect executive dysfunction in individuals with SUDs. It is simple to administer and does not require sophisticated equipment, making it suitable for OPD settings.^2,16

Recent studies have reinforced the role of brief frontal assessments in substance use and other neuropsychiatric populations. Maharjan et al. demonstrated consistent executive dysfunction across alcohol-dependent cohorts, emphasizing the clinical importance of rapid cognitive screening tools in addiction settings.¹⁷ Similarly, Aiello et al. provided updated normative data and validation evidence for the FAB, supporting its continued reliability and cross-cultural applicability in evaluating frontal lobe integrity.¹⁸

This study had a few limitations. It was cross-sectional in design, so it cannot establish a causal relationship between substance use and executive dysfunction. Also, the sample size was relatively small. Neuroimaging studies or more comprehensive neuropsychological assessments would provide deeper insights, but the FAB offers a practical starting point for evaluating cognitive functions in busy clinical settings.

CONCLUSION

This study found that executive dysfunction is significantly more common in individuals with SUDs than in the normal population. Among the three groups studied, cannabis users showed the most pronounced impairment. There was a negative correlation between the duration of substance use and FAB scores in cannabis and opioid users, indicating that longer substance use may worsen executive functioning. The FAB was found to be a helpful screening tool to identify these deficits. Early identification of executive dysfunction can improve the overall management and rehabilitation outcomes in patients with SUDs.